Market Evaluation Of Very Low Dose Glucagon (VLDG) For The Treatment Of Insulin-induced Nocturnal Hypoglycaemia

点击翻译按钮获取中文摘要

Arestat™ is Arecor’s protein stabilization technology. The application of Arestat™ toglucagon, a drug used in the treatment of hypoglycaemia in emergency situations, has allowedthe development of a novel aqueous dose of glucagon. The current marketed versions ofglucagon are lyophilized powders requiring reconstitution prior to administration. Thesepresentations are not in the correct format to be used as Very Low Dose Glucagon (VLDG)for the treatment of nocturnal hypoglycaemia which requires automated administration of aliquid dose in small quantities. The incidence of nocturnal hypoglycaemia in insulindependentType I diabetics is high, however, there are no VLDG products on the market totreat this condition. Arecor, therefore, are considering utilizing their novel aqueousformulation of glucagon to develop a VLDG product to address the market need. A marketresearch study which engages opinion leaders in the field is urgently required to ascertain thetechnical feasibility and commercial potential of a VLDG product.